Bone and Cancer
Bone and Cancer
Bone and CancerBone and Cancer Foundation, PO Box 287452 Bone and Cancer New York, NY 10128-0025  
Toll Free: 888 862-0999 Bone and Cancer Email:  
Bone and Cancer

Clinical Trials

ARICEPT (donepezil hydrochloride)

The following drug information is obtained from various newswires, published medical journal articles, and medical conference presentations.


Approval Status:

Approved December 1996

Specific Treatments:

Alzheimer's Disease

General Information

Aricept has been approved for the symptomatic treatment of mild to moderate Alzheimer's disease. Aricept is effective in improving cognition and patient function in people with mild to moderate Alzheimer's Disease.

Clinical Results

Controlled clinical trials in over 900 subjects demonstrated that more than 80% of subjects taking Aricept either improved or exhibited no further demonstration in tests of cognition over the course of the studies. In an assessment of patient function, which includes general function, cognition, behavior and activities of daily living, clinicians rated approximately two times as many subjects on Aricept as improved in comparison to placebo after 24 weeks of treatment.

Mechanism of Action

Aricept is a new reversible inhibitor of the enzyme acetylcholinesterase. Acetylcholinesterase is an enzyme, which breaks down the neurotransmitter acetylcholine. Aricept may allow a greater concentration of acetylcholine in the brain, thereby improving cholinergic function. Acetylcholine, associated with memory and learning, is in short supply in subjects with Alzheimer's disease.

 How To Order Publications:

Information About

Clinical Trials



















  Copyright 2011 - The Bone and Cancer Foundation